Benzinga | Nov 3, 2021 09:20AM EDT

Oppenheimer Maintains Outperform on Sage Therapeutics, Lowers Price Target to $80

Oppenheimer analyst Jay Olson maintains Sage Therapeutics (NASDAQ:SAGE) with a Outperform and lowers the price target from $84 to $80.